Alkermes (ALKS) Change in Acquisitions & Divestments (2010 - 2026)
Alkermes' (ALKS) quarterly Change in Acquisitions & Divestments came in at $42.6 million in Q1 2026, down 62.46% year-on-year from $113.5 million in Q1 2025, and down 88.7% on a QoQ basis from $377.1 million in Q4 2025.
Alkermes (ALKS) Change in Acquisitions & Divestments (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Change in Acquisitions & Divestments data on file, last reported at $42.6 million in Q1 2026.
- On a quarterly basis, Change in Acquisitions & Divestments fell 62.46% year-over-year to $42.6 million in Q1 2026; TTM through Mar 2026 was $626.6 million, a 83.6% increase from a year earlier, with the FY2025 full-year figure at $697.5 million, up 124.79% from the prior year.
- Change in Acquisitions & Divestments for Q1 2026 stood at $42.6 million, down from $377.1 million in the prior quarter.
- Over the last five years, Change in Acquisitions & Divestments for ALKS reached as high as $377.1 million in Q4 2025 and fell as low as $42.6 million in Q1 2026.
- Historically, Change in Acquisitions & Divestments has averaged $99.3 million across 5 years, with a median of $82.5 million in 2024.
- Across the five-year window, Change in Acquisitions & Divestments jumped 341.06% in 2025 and plunged 62.46% in 2026, its largest moves.
- Year by year, Change in Acquisitions & Divestments stood at $90.6 million in 2022, then retreated by 29.85% to $63.6 million in 2023, then surged by 34.48% to $85.5 million in 2024, then jumped by 341.06% to $377.1 million in 2025, then tumbled by 88.7% to $42.6 million in 2026.
- Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $42.6 million in Q1 2026, $377.1 million in Q4 2025, and $125.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.61 Mn |
| Mar 31, 2026 | 42.61 Mn |
| Dec 31, 2025 | 377.11 Mn |
| Dec 31, 2025 | 377.11 Mn |
| Sep 30, 2025 | 125.31 Mn |
| Sep 30, 2025 | 125.31 Mn |
| Jun 30, 2025 | 81.59 Mn |
| Jun 30, 2025 | 81.59 Mn |
| Mar 31, 2025 | 113.49 Mn |
| Mar 31, 2025 | 113.49 Mn |
| Dec 31, 2024 | 85.50 Mn |
| Dec 31, 2024 | 85.50 Mn |
| Sep 30, 2024 | 85.84 Mn |
| Sep 30, 2024 | 85.84 Mn |
| Jun 30, 2024 | 56.46 Mn |
| Jun 30, 2024 | 56.46 Mn |
| Mar 31, 2024 | 82.49 Mn |
| Mar 31, 2024 | 82.49 Mn |
| Dec 31, 2023 | 63.58 Mn |
| Dec 31, 2023 | 63.58 Mn |